Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

Ryan Crowe – Vice President-Investor Relations

Leonard Schleifer – President and Chief Executive Officer

George Yancopoulos – President and Chief Scientific Officer

Marion McCourt – Executive Vice President and Head-Commercial

Bob Landry – Executive Vice President and Chief Financial Officer

Conference Call Participants

Evan Seigerman – BMO Capital Markets

Mohit Bansal – Wells Fargo

Chris Raymond – Piper Sandler

Colin Bristow – UBS

Tyler Van Buren – TD Cowen

Carter Gould – Barclays

Robyn Karnauskas – Truist Securities

Salveen Richter – Goldman Sachs

Brian Abrahams – RBC Capital Markets

Yatin Suneja – Guggenheim

Dane Leone – Raymond James

Brian Skorney – Baird

Operator

Welcome to the Regeneron Pharmaceuticals Third Quarter 2023 Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.

I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin.

Ryan Crowe

Thank you, Shannon. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our third quarter 2023 earnings conference call. An archive and transcript of this webcast will be available on our Investor Relations website shortly after the call ends.

Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.

I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron. Such statements may include, but are not limited to those related to Regeneron and its products and businesses -- business, financial forecast and guidance, revenue diversification, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement issues, intellectual property, pending litigation and other proceedings, and competition.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended September 30, 2023, which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.